NEW YORK (GenomeWeb) — Hologic said this week that its molecular diagnostics sales declined 8 percent year over year in its fiscal second quarter, but increased 1 percent when adjusted for the divestiture last year of its Lifecodes transplant diagnostics segment.

Hologic's adjusted growth in molecular diagnostics, which includes the company's Panther testing system and associated Aptima assays, helped mitigate an overall 2 percent decline in revenues, or 4 percent on adjusted basis, in its Diagnostics segment. Overall, the firm's revenues were up 2 percent year over year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

Jul
14
Sponsored by
Agilent Technologies

This online seminar will outline a recent example of the use of molecular barcoding in combination with next-generation sequencing to detect somatic mosaicism in cancer patients.